Search Results - "Nishino, Mizuki"

Monitoring immune-checkpoint blockade: response evaluation and biomarker development by Nishino, Mizuki, Ramaiya, Nikhil H., Hatabu, Hiroto, Hodi, F. Stephen

“…Key Points A subset of patients receiving immune-checkpoint inhibitor therapy develop unconventional response patterns (termed 'pseudoprogression'), in which…”
Get full text

Imaging of Cancer Immunotherapy: Current Approaches and Future Directions by Nishino, Mizuki, Hatabu, Hiroto, Hodi, F Stephen

“…Cancer immunotherapy using immune-checkpoint inhibitors has emerged as an effective treatment option for a variety of advanced cancers in the past decade…”
Get full text

Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment by Nishino, Mizuki

“…The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy…”
Get full text

Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy by Nishino, Mizuki, Sholl, Lynette M, Hatabu, Hiroto, Ramaiya, Nikhil H, Hodi, F. Stephen

“…Among three patients with melanoma receiving anti–PD-1 antibodies, the use of checkpoint blockers led to the development of serious autoimmune pneumonitis, a…”
Get full text

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements by NISHINO, Mizuki, GIOBBIE-HURDER, Anita, GARGANO, Maria, SUDA, Margaret, RAMAIYA, Nikhil H, HODI, F. Stephen

“…Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements,…”
Get full text

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course by Nishino, Mizuki, Ramaiya, Nikhil H, Awad, Mark M, Sholl, Lynette M, Maattala, Jennifer A, Taibi, Myriam, Hatabu, Hiroto, Ott, Patrick A, Armand, Philippe F, Hodi, F Stephen

“…Investigate the clinical characteristics, radiographic patterns, and treatment course of PD-1 inhibitor-related pneumonitis in advanced cancer patients. Among…”
Get full text

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models by Engstrom, Lars D, Aranda, Ruth, Lee, Matthew, Tovar, Elizabeth A, Essenburg, Curt J, Madaj, Zachary, Chiang, Harrah, Briere, David, Hallin, Jill, Lopez-Casas, Pedro P, Baños, Natalia, Menendez, Camino, Hidalgo, Manuel, Tassell, Vanessa, Chao, Richard, Chudova, Darya I, Lanman, Richard B, Olson, Peter, Bazhenova, Lyudmilla, Patel, Sandip Pravin, Graveel, Carrie, Nishino, Mizuki, Shapiro, Geoffrey I, Peled, Nir, Awad, Mark M, Jänne, Pasi A, Christensen, James G

“…exon 14 deletion ( ex14 del) mutations represent a novel class of non-small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a…”
Get full text

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy by Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D

“…Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately…”
Get full text

MUC5B Promoter Polymorphism and Interstitial Lung Abnormalities by Hunninghake, Gary M, Hatabu, Hiroto, Okajima, Yuka, Gao, Wei, Dupuis, Josée, Latourelle, Jeanne C, Nishino, Mizuki, Araki, Tetsuro, Zazueta, Oscar E, Kurugol, Sila, Ross, James C, San José Estépar, Raúl, Murphy, Elissa, Steele, Mark P, Loyd, James E, Schwarz, Marvin I, Fingerlin, Tasha E, Rosas, Ivan O, Washko, George R, O'Connor, George T, Schwartz, David A

“…Variants in the gene encoding mucin 5B ( MUC5B ) have been associated with interstitial fibrosis. This study shows a relationship between the presence of the…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer by Ricciuti, Biagio, Recondo, Gonzalo, Spurr, Liam F, Li, Yvonne Y, Lamberti, Giuseppe, Venkatraman, Deepti, Umeton, Renato, Cherniack, Andrew D, Nishino, Mizuki, Sholl, Lynette M, Shapiro, Geoffrey I, Awad, Mark M, Cheng, Michael L

“…DNA damage response and repair (DDR) gene alterations are associated with increased tumor-infiltrating lymphocytes, higher genomic instability, and higher…”
Get full text

State of the art: Response assessment in lung cancer in the era of genomic medicine by Nishino, Mizuki, Hatabu, Hiroto, Johnson, Bruce E, McLoud, Theresa C

“…Tumor response assessment has been a foundation for advances in cancer therapy. Recent discoveries of effective targeted therapy for specific genomic…”
Get full text

Association Between Interstitial Lung Abnormalities and All-Cause Mortality by Putman, Rachel K, Hatabu, Hiroto, Araki, Tetsuro, Gudmundsson, Gunnar, Gao, Wei, Nishino, Mizuki, Okajima, Yuka, Dupuis, Josée, Latourelle, Jeanne C, Cho, Michael H, El-Chemaly, Souheil, Coxson, Harvey O, Celli, Bartolome R, Fernandez, Isis E, Zazueta, Oscar E, Ross, James C, Harmouche, Rola, Estépar, Raúl San José, Diaz, Alejandro A, Sigurdsson, Sigurdur, Gudmundsson, Elías F, Eiríksdottír, Gudny, Aspelund, Thor, Budoff, Matthew J, Kinney, Gregory L, Hokanson, John E, Williams, Michelle C, Murchison, John T, MacNee, William, Hoffmann, Udo, O’Donnell, Christopher J, Launer, Lenore J, Harrris, Tamara B, Gudnason, Vilmundur, Silverman, Edwin K, O’Connor, George T, Washko, George R, Rosas, Ivan O, Hunninghake, Gary M

“…IMPORTANCE: Interstitial lung abnormalities have been associated with lower 6-minute walk distance, diffusion capacity for carbon monoxide, and total lung…”
Get full text

Imaging of Precision Therapy for Lung Cancer: Current State of the Art by Park, Hyesun, Sholl, Lynette M, Hatabu, Hiroto, Awad, Mark M, Nishino, Mizuki

“…Advances in characterization of molecular and genomic abnormalities specific to lung cancer have made precision therapy the current standard of care for lung…”
Get full text

Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions by Nishino, Mizuki, Giobbie-Hurder, Anita, Manos, Michael P, Bailey, Nancy, Buchbinder, Elizabeth I, Ott, Patrick A, Ramaiya, Nikhil H, Hodi, F Stephen

“…Characterize tumor burden dynamics during PD-1 inhibitor therapy and investigate the association with overall survival (OS) in advanced melanoma. The study…”
Get full text

Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care by Nishino, Mizuki, Hatabu, Hiroto, Sholl, Lynette M, Ramaiya, Nikhil H

“…Recent advances in understanding the molecular mechanisms of cancer have opened a new era of precision medicine for cancer treatment. Precision cancer…”
Get full text

Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study by Araki, Tetsuro, Putman, Rachel K, Hatabu, Hiroto, Gao, Wei, Dupuis, Josée, Latourelle, Jeanne C, Nishino, Mizuki, Zazueta, Oscar E, Kurugol, Sila, Ross, James C, San José Estépar, Raúl, Schwartz, David A, Rosas, Ivan O, Washko, George R, O'Connor, George T, Hunninghake, Gary M

“…The relationship between the development and/or progression of interstitial lung abnormalities (ILA) and clinical outcomes has not been previously…”
Get full text

Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis–Associated Interstitial Lung Disease: A Prospective Cohort Study by Sparks, Jeffrey A., He, Xintong, Huang, Jie, Fletcher, Elaine A., Zaccardelli, Alessandra, Friedlander, H. Maura, Gill, Ritu R., Hatabu, Hiroto, Nishino, Mizuki, Murphy, David J., Iannaccone, Christine K., Mahmoud, Taysir G., Frits, Michelle L., Lu, Bing, Rosas, Ivan O., Dellaripa, Paul F., Weinblatt, Michael E., Karlson, Elizabeth W., Shadick, Nancy A., Doyle, Tracy J.

“…Objective To evaluate rheumatoid arthritis (RA) disease activity and risk of RA‐associated interstitial lung disease (RA‐ILD). Methods We investigated disease…”
Get full text

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement by Sears, Catherine R, Peikert, Tobias, Possick, Jennifer D, Naidoo, Jarushka, Nishino, Mizuki, Patel, Sandip P, Camus, Philippe, Gaga, Mina, Garon, Edward B, Gould, Michael K, Limper, Andrew H, Montgrain, Philippe R, Travis, William D, Rivera, M Patricia

“…Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening…”
Get full text

The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis by Suh, Chong Hyun, Kim, Kyung Won, Pyo, Junhee, Hatabu, Hiroto, Nishino, Mizuki

“…•The overall incidence of ALK inhibitor pneumonitis was 2.14% in advanced NSCLC.•Patients from Japanese cohorts had a higher incidence of ALK-inhibitor…”
Get full text